<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405119</url>
  </required_header>
  <id_info>
    <org_study_id>LAV104616</org_study_id>
    <nct_id>NCT00405119</nct_id>
  </id_info>
  <brief_title>A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.</brief_title>
  <official_title>A Randomized, Double-blind, Four Period Cross-over Comparison of the Effect of Two Doses Lavoltidine, Esomeprazole, and Placebo on 24 Hour Gastric pH and Frequency of Heartburn in Symptomatic GERD Subjects Without Esophageal Erosions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current treatment for gastroesophageal reflux disease (GERD) confirms an unmet need in
      patients, based on slow onset of action and an inability to provide 24-hour gastric-acid
      suppression. Clinical data on AH234844 demonstrates a rapid onset of action, high potency,
      and prolonged duration of effect. The present study endeavors, in part, to compare
      lavoltidine to two GERD drugs, NEXIUM and ranitidine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A three-part study in healthy male volunteers to determine the most effective of four
      different lavoltidine doses on gastric pH and to compare the most effective dose with NEXIUM
      (esomeprazole) 40mg for the inhibition of gastric-acid secretion and with ranitidine
      (300mg/day) for the amount of pharmacodynamic tolerance
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pH over 24hours</measure>
    <time_frame>over 24hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>%24 hours pH&gt;4 Median gastric pH Adverse events</measure>
    <time_frame>over 24 hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">92</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>Reflux, Gastroesophageal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AH23844 (lavoltidine)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEXIUM (esomeprazole)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZANTAC (ranitidine)</intervention_name>
    <other_name>AH23844 (lavoltidine)</other_name>
    <other_name>NEXIUM (esomeprazole)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subject must have a Body Mass Index (BMI) from 19-30 kg/m2

          -  Subject does not present with abnormal clinical lab findings

          -  Subject is able to tolerate a nasogastric pH electrode.

        Exclusion criteria:

          -  Subject is Helicobacter-positive on a C13 urea breath test

          -  Subject has a baseline median 24-hour gastric pH&gt;3

          -  For Part B of the study, subjects are CYP 2C19 poor metabolizers.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2006</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tolerance</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>ranitidine</keyword>
  <keyword>esomeprazole</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>gastroesophageal reflux disease (GERD)</keyword>
  <keyword>AH23844</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
    <mesh_term>Loxtidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

